Aksana Jones - Search Results

Year	Number of Results
2015	1
2016	4
2017	2
2019	2
2020	1
2021	3
2022	1
2024	0

1

Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach.

Cohen-Barak O, Radivojevic A, Jones A, Fiedler-Kelly J, Gillespie M, Brennan M, Gutman D, Rasamoelisolo M, Hallak H, Loupe P, Kessler Y, Ning X, Levi M, Ahn AH, Rabinovich-Guilatt L. Cohen-Barak O, et al. Among authors: jones a. Cephalalgia. 2021 Sep;41(10):1065-1074. doi: 10.1177/03331024211007789. Epub 2021 May 17. Cephalalgia. 2021. PMID: 34000848 Clinical Trial.

2

Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials.

Jones AK, Ngaimisi E, Gopalakrishnan M, Young MA, Laffont CM. Jones AK, et al. Clin Pharmacokinet. 2021 Apr;60(4):527-540. doi: 10.1007/s40262-020-00957-0. Epub 2020 Nov 2. Clin Pharmacokinet. 2021. PMID: 33135125 Free PMC article. Clinical Trial.

3

Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts.

Jones A, Saini J, Kriel B, Via LE, Cai Y, Allies D, Hanna D, Hermann D, Loxton AG, Walzl G, Diacon AH, Romero K, Higashiyama R, Liu Y, Berg A. Jones A, et al. BMC Infect Dis. 2022 Apr 2;22(1):327. doi: 10.1186/s12879-022-07308-3. BMC Infect Dis. 2022. PMID: 35366820 Free PMC article.

4

Power Determination During Drug Development: Is Optimizing the Sample Size Based on Exposure-Response Analyses Underutilized?

Jones AK, Salem AH, Freise KJ. Jones AK, et al. CPT Pharmacometrics Syst Pharmacol. 2019 Mar;8(3):138-145. doi: 10.1002/psp4.12380. Epub 2019 Feb 5. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 30659774 Free PMC article.

5

Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation.

Wang H, Jones AK, Dvorak CC, Huang L, Orchard P, Ivaturi V, Long-Boyle J. Wang H, et al. Among authors: jones ak. Biol Blood Marrow Transplant. 2019 Aug;25(8):1603-1610. doi: 10.1016/j.bbmt.2019.04.017. Epub 2019 Apr 17. Biol Blood Marrow Transplant. 2019. PMID: 31002993 Free PMC article. Clinical Trial.

6

Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.

Freise KJ, Dunbar M, Jones AK, Hoffman D, Enschede SL, Wong S, Salem AH. Freise KJ, et al. Among authors: jones ak. Cancer Chemother Pharmacol. 2016 Oct;78(4):847-53. doi: 10.1007/s00280-016-3144-1. Epub 2016 Sep 1. Cancer Chemother Pharmacol. 2016. PMID: 27586967

7

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.

Freise KJ, Jones AK, Eckert D, Mensing S, Wong SL, Humerickhouse RA, Awni WM, Salem AH. Freise KJ, et al. Among authors: jones ak. Clin Pharmacokinet. 2017 May;56(5):515-523. doi: 10.1007/s40262-016-0453-9. Clin Pharmacokinet. 2017. PMID: 27638334 Clinical Trial.

8

Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.

Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH. Jones AK, et al. AAPS J. 2016 Sep;18(5):1192-1202. doi: 10.1208/s12248-016-9927-9. Epub 2016 May 27. AAPS J. 2016. PMID: 27233802 Clinical Trial.

9

Scaling Approaches for Pediatric Dose Selection: The Fremanezumab (AJOVY^®) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data from a Phase 1 Study.

Jones A, Cohen-Barak O, Radivojevic A, Fiedler-Kelly J. Jones A, et al. Pharmaceutics. 2021 May 24;13(6):785. doi: 10.3390/pharmaceutics13060785. Pharmaceutics. 2021. PMID: 34074002 Free PMC article.

10

Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.

Freise KJ, Jones AK, Menon RM, Verdugo ME, Humerickhouse RA, Awni WM, Salem AH. Freise KJ, et al. Among authors: jones ak. Hematol Oncol. 2017 Dec;35(4):679-684. doi: 10.1002/hon.2373. Epub 2016 Dec 16. Hematol Oncol. 2017. PMID: 27982454

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

11 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year